Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2016 -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Company will be presenting at the Stifel Healthcare Conference taking place November 15 to 16, 2016, at the Lotte New York Palace Hotel, New York, NY. Achaogen management will present at 2:15 p.m. Eastern Time on Wednesday, November 16th, 2016.
A live audio webcast of the presentation will be available in the "Investors" section of Achaogen’s website, www.achaogen.com. A replay of the presentation will be archived for 30 days following the conference for those unable to listen live.
About Achaogen
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. For more information, please visit www.achaogen.com.
Investor Contact: Hans Vitzthum 212.915.2568 [email protected] Media Contact: Denise Powell 510.703.9491 [email protected]
